Get the Stockscreener App
19.00
5.38%
-1.08
After Hours:
19.00
Neurogene Inc stock is traded at $19.00, with a volume of 123.02K.
It is down -5.38% in the last 24 hours and down -1.14% over the past month.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
See More
Previous Close:
$20.08
Open:
$20.07
24h Volume:
123.02K
Relative Volume:
0.78
Market Cap:
$271.17M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-4.76%
1M Performance:
-1.14%
6M Performance:
+6.86%
1Y Performance:
-52.92%
1-Day Range:
$18.77
$20.42
1-Week Range:
$18.37
$20.72
52-Week Range:
$6.875
$74.49
Neurogene Inc Stock (NGNE) Company Profile
Name
Neurogene Inc
Sector
Industry
Phone
(877) 237-5020
Address
535 W 24TH STREET, NEW YORK
Compare NGNE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
19.00 | 265.46M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Craig Hallum | Buy |
| May-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Mar-21-24 | Initiated | William Blair | Outperform |
| Jan-08-24 | Initiated | H.C. Wainwright | Buy |
| Jan-05-24 | Initiated | Stifel | Buy |
| Jan-04-24 | Initiated | TD Cowen | Outperform |
View All
Neurogene Inc Stock (NGNE) Latest News
Regression analysis insights on Neurogene Inc. performance2025 Trade Ideas & AI Powered Market Entry Strategies - Newser
Will Neurogene Inc. stock recover after recent dropIPO Watch & Risk Managed Investment Signals - Newser
Using data tools to time your Neurogene Inc. exitMarket Growth Summary & Risk Managed Trade Strategies - Newser
Neurogene Inc. stock chart pattern explainedMarket Performance Summary & Fast Exit and Entry Strategy Plans - Newser
Predicting Neurogene Inc. trend using moving averagesPortfolio Growth Summary & Community Supported Trade Ideas - Newser
Tick level data insight on Neurogene Inc. volatilityJuly 2025 Breakouts & High Conviction Trade Alerts - Newser
Will a bounce in Neurogene Inc. offer an exitJuly 2025 Weekly Recap & Accurate Buy Signal Notifications - Newser
Neurogene Inc. stock trendline breakdownDividend Hike & Accurate Entry/Exit Alerts - Newser
How to escape a deep drawdown in Neurogene Inc.Entry Point & Long-Term Capital Growth Strategies - Newser
Should you hold or exit Neurogene Inc. now2025 Big Picture & Safe Entry Zone Identification - Newser
Neurogene Inc. stock trend forecastQuarterly Risk Review & Free Weekly Chart Analysis and Trade Guides - Newser
Neurogene Inc. stock volume spike explained2025 Top Decliners & Technical Buy Zone Confirmations - Newser
Is Neurogene Inc. forming a bottoming baseInsider Buying & Stock Portfolio Risk Control - Newser
Pattern recognition hints at Neurogene Inc. upside2025 Analyst Calls & Fast Entry High Yield Stock Tips - Newser
neurogene inc. stock trend forecastM&A Rumor & Stock Portfolio Risk Control - Newser
Using Ichimoku Cloud for Neurogene Inc. technicalsMarket Risk Summary & Capital Efficient Trading Techniques - Newser
How to build a custom watchlist for Neurogene Inc.Trend Reversal & Fast Exit/Entry Strategy Plans - Newser
Nuveen LLC Purchases Shares of 27,482 Neurogene Inc. $NGNE - MarketBeat
regression analysis insights on neurogene inc. performance2025 Top Decliners & Expert Approved Trade Ideas - Newser
Will Neurogene Inc. rebound enough to break evenMarket Movement Recap & Pattern Based Trade Signal System - Newser
News impact scoring models applied to Neurogene Inc.July 2025 Fed Impact & Stepwise Trade Signal Guides - Newser
Applying Elliott Wave Theory to Neurogene Inc.July 2025 Movers & Safe Entry Point Identification - Newser
What technical models suggest about Neurogene Inc.’s comeback2025 Market Trends & Weekly Market Pulse Updates - Newser
will neurogene inc. rebound enough to break even2025 Biggest Moves & AI Powered Buy/Sell Recommendations - Newser
using data tools to time your neurogene inc. exitQuarterly Market Review & High Return Trade Opportunity Guides - Newser
Has Neurogene Inc. found a price floor2025 Volume Leaders & Expert Curated Trade Ideas - Newser
How moving averages guide Neurogene Inc. tradingForecast Cut & Free Weekly Chart Analysis and Trade Guides - Newser
How sentiment analysis helps forecast Neurogene Inc.July 2025 Selloffs & Verified Trade Idea Suggestions - Newser
What earnings revisions data tells us about Neurogene Inc.July 2025 Trade Ideas & Safe Capital Growth Plans - Newser
Are Bears Losing Grip on Neurogene Inc.Portfolio Return Report & Smart Allocation Stock Reports - beatles.ru
Neurogene Inc Stock (NGNE) Financials Data
There is no financial data for Neurogene Inc (NGNE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):